Virpax to Develop CBD Nasal Spray for Epilepsy

Virpax to Develop CBD Nasal Spray for Epilepsy

313594

Virpax to Develop CBD Nasal Spray for Epilepsy

Virpax Pharmaceuticals has acquired exclusive worldwide rights from Nanomerics to develop a nasal spray of cannabidiol to treat epilepsy in adults and children, including those with Dravet syndrome. Under the agreement, Virpax can develop, manufacture, and sell VRP324, an investigational formulation of cannabidiol (CBD) administered using a nasal spray to enhance delivery directly to the brain. Cannabidiol is derived from the cannabis plant but does not have psychoactive effects. Nanomerics already has begun preclinical studies of…

You must be logged in to read/download the full post.